Your browser doesn't support javascript.
loading
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill, Brian T; Rybicki, Lisa A; Urban, Theresa A; Lucena, Mariana; Jagadeesh, Deepa; Gerds, Aaron T; Dean, Robert M; Sobecks, Ronald M; Pohlman, Brad; Bolwell, Brian; Kalaycio, Matt E; Hamilton, Betty K; Copelan, Edward A; Majhail, Navneet S.
Afiliação
  • Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina. Electronic addre
  • Rybicki LA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Urban TA; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio.
  • Lucena M; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio.
  • Jagadeesh D; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Gerds AT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Dean RM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Sobecks RM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Pohlman B; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Bolwell B; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Kalaycio ME; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Hamilton BK; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Copelan EA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio; Levine Cancer Institute, Charlotte, North Carolina.
  • Majhail NS; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Biol Blood Marrow Transplant ; 26(2): 262-271, 2020 02.
Article em En | MEDLINE | ID: mdl-31610237
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos